Thursday November 8, 2012: 5:00 to 7:00 p.m.
Registration and Networking: 4:30 - 5:00 p.m.
Panel Discussion: 5:00 - 6:00 p.m.
Networking: 6:00 - 7:00 p.m.
Anlyan Center, Yale University
300 Cedar Street
New Haven, CT 06520
This event is FREE for all attendees.
Crossroads Venture Group
Please register on-site at tomorrow's event starting at 4:30 PM.
Online registration is now closed.
At CVG's Second Thursday event in November, panelists will discuss Point-of-care testing (POCT). POCT is poised to revolutionize health care costs and speed. They are readily deployed, bring cash directly to physicians and require limited approvals. Point-of-Care Testing is disintermediating the multi-billion laboratory business completely disrupting the flow of funds. We are at the beginning of this transformation. It has already attracted significant venture investment over the past 5 years.
Come hear three experts in this trend - Harry Penner of New Haven Pharma and Vincent Pierribone of Affinimark are two premiere entrepreneurs in Point-of-Care Testing. Konstantine Drakonikis of Launch Capital is actively investing in this area. If you are an investor or entrepreneur interested in IT, Telecom, Life Sciences or Advanced Manufacturing, this is a trend you need to know about. It presents a wide variety of opportunities because it is such a disruptive trend.
Konstantine Drakonakis is the New Haven Director at Launch Capital. He is an experienced early stage investor focused on proprietary technologies in the tri-state NY region. As an "Entrepreneurial Engineer", Konstantine gravitates to technology companies within the software, med-tech and green-tech markets.
Harry H. Penner, Jr and Vincent Pieribone of Affinimark Technologies Inc., a private bioscience company based in New Haven. Affinimark Technologies develops proprietary medical diagnostic products addressing market opportunities and serious unmet medical/surgical needs. Its lead product, CerebrostripTM, is a strip-based diagnostic test, derived from Affinimark’s own cutting edge research, that will quickly and cost-effectively provide a definitive determination whether a patient has suffered a cerebrospinal fluid leak as a result of surgery or trauma. No such product is currently available, resulting in significant risk to the patient and cost to the healthcare system.
B Round Sponsors
Robinson & Cole
Shipman & Goodwin
Updike, Kelly & Spellacy, P.C.
Wiggin & Dana
A Round Sponsors
of New Haven
CCEI - University of Connecticut
Yale University - Office of Cooperative Research
Venture Capital Firm SponsorsCanaan Partners
Stonehenge Growth Capital
Lead Professional Services Firms SponsorsO'Connor Davies Munns & Dobbins
Pullman & Comley LLC
Carter Morse & Mathias
Supporting Professional Services FirmFairfield Partners